Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study

Frontiers in urology Pub Date : 2022-12-12 DOI:10.3389/fruro.2022.1069045

R. Moreira, M. Fernandes, M. Monteiro, F. Luiz, Erika Simplicio Silva, P. Andrade, Mayara Batista Pinto, Letycia Lima, Astrid Silva, J. Nunez, D. Freitas, L. H. de Lima Araújo, Caio Vinícius Teles Rossini, P. Aguiar

{"title":"Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study","authors":"R. Moreira, M. Fernandes, M. Monteiro, F. Luiz, Erika Simplicio Silva, P. Andrade, Mayara Batista Pinto, Letycia Lima, Astrid Silva, J. Nunez, D. Freitas, L. H. de Lima Araújo, Caio Vinícius Teles Rossini, P. Aguiar","doi":"10.3389/fruro.2022.1069045","DOIUrl":null,"url":null,"abstract":"Previous studies suggested that obesity pro-inflammatory state could improve immune checkpoint inhibitors (ICI) clinical efficacy. This is a retrospective, multicenter, and observational study that included patients treated in a private Brazilian Oncology Group. Primary outcomes were the association of body mass index (BMI) category with overall survival (OS) and progression free survival (PFS). Secondary outcomes were association between BMI and objective response rate (ORR). In the total cohort, 448 patients were classified as a normal weight (43%), overweight (36%), obese (17%) and underweight (4%). The patients were predominantly male gender (62%), with stage IV lung cancer (57%) and melanoma (19%). The obese group (BMI ≥ 30 kg/m2) had a not statistically significant longer median OS than the non-obese group (BMI < 30 kg/m2) - 21.8 months (95% CI NR - NR) versus 14.9 months (95% CI 8.3 - 21.5); HR = 0.82, (95% CI 0.57 - 1.18, P = 0.28). Obese patients treated with anti-CTLA4 did not reach the mOS, while the non-obese group had a mOS of 23.1 months (P = 0.04). PFS did not differ between subgroups. Obese patients had also lower ORR, but without reaching statistical significance. In conclusion, this study did not report an improved OS among high BMI patients treated with ICI.","PeriodicalId":73113,"journal":{"name":"Frontiers in urology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fruro.2022.1069045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Previous studies suggested that obesity pro-inflammatory state could improve immune checkpoint inhibitors (ICI) clinical efficacy. This is a retrospective, multicenter, and observational study that included patients treated in a private Brazilian Oncology Group. Primary outcomes were the association of body mass index (BMI) category with overall survival (OS) and progression free survival (PFS). Secondary outcomes were association between BMI and objective response rate (ORR). In the total cohort, 448 patients were classified as a normal weight (43%), overweight (36%), obese (17%) and underweight (4%). The patients were predominantly male gender (62%), with stage IV lung cancer (57%) and melanoma (19%). The obese group (BMI ≥ 30 kg/m2) had a not statistically significant longer median OS than the non-obese group (BMI < 30 kg/m2) - 21.8 months (95% CI NR - NR) versus 14.9 months (95% CI 8.3 - 21.5); HR = 0.82, (95% CI 0.57 - 1.18, P = 0.28). Obese patients treated with anti-CTLA4 did not reach the mOS, while the non-obese group had a mOS of 23.1 months (P = 0.04). PFS did not differ between subgroups. Obese patients had also lower ORR, but without reaching statistical significance. In conclusion, this study did not report an improved OS among high BMI patients treated with ICI.

查看原文本刊更多论文

转移性癌症患者的体重指数和免疫检查点抑制剂疗效：一项巴西回顾性研究

先前的研究表明，肥胖促炎状态可以提高免疫检查点抑制剂（ICI）的临床疗效。这是一项回顾性、多中心和观察性研究，包括在一家私人巴西肿瘤小组接受治疗的患者。主要结果是体重指数（BMI）类别与总生存期（OS）和无进展生存期（PFS）的相关性。次要结果是BMI和客观有效率（ORR）之间的相关性。在整个队列中，448名患者被分为正常体重（43%）、超重（36%）、肥胖（17%）和体重不足（4%）。患者主要为男性（62%），癌症IV期（57%）和黑色素瘤（19%）。肥胖组（BMI≥30kg/m2）的中位OS比非肥胖组（BMI<30kg/m2）长21.8个月（95%CI NR-NR）和14.9个月（95%CI 8.3-21.5），无统计学意义；HR=0.82，（95%CI 0.57-1.18，P=0.28）。接受抗CTLA4治疗的肥胖患者没有达到mOS，而非肥胖组的mOS为23.1个月（P=0.04）。各亚组的PFS没有差异。肥胖患者的ORR也较低，但没有达到统计学意义。总之，这项研究没有报告在接受ICI治疗的高BMI患者中OS的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in urology

CiteScore

0.40

自引率

0.00%

发文量